Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

NEXT STORY
G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival
PREV STORY
Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Nasal Swab Test Market Size Is Expected To Reach Around USD 150.7 Million by 2026, at a CAGR of 3.4% Growth: Facts & Factors

author_avatar
NASDAQ Market News

INC Research Enhances Therapeutic Expertise With Key Promotions in General Medicine and CNS

RALEIGH, N.C., Aug. 25, 2015 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a ...

author_avatar
NASDAQ Market News

Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer

author_avatar
NASDAQ Market News